Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics

Inclusion Criteria Patient must: Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current episode. PCP must be documented by observation of > 1 cluster of organisms in sputum, bronchial secretion, or lung tissue. Have clinical symptoms of respiratory disease or radiologic abnormalities. Exclusion Criteria Patient cannot have significant emotional disorder. Concurrent Medication: Excluded: Drugs likely to be bone marrow toxic. Investigational drugs. Prior Medication: Excluded: Three patients in each group cannot have had zidovudine (AZT) for at least 2 months prior to administration of trimetrexate.